RxSight Hits 300,000 Implants, Reports 93.1% 20/20 Clinical Outcomes
RxSight has achieved over 300,000 Light Adjustable Lens implants since launch, marking a major adoption milestone in customized vision correction. RxSight will present 35 scientific papers at ASCRS 2026, reporting 93.1% of bilateral patients achieved 20/20 distance with J1 near vision and 91.2% accuracy within 0.50 diopters.
1. Milestone of 300,000 Implants
RxSight announced that over 300,000 Light Adjustable Lens implants have been performed since product launch, underscoring rapid adoption of its post-surgical vision adjustment technology and marking a key commercial milestone for customized cataract correction.
2. Clinical Data at ASCRS 2026
At ASCRS 2026, RxSight will feature 15 papers, 19 posters and one session, including data showing 93.1% of bilateral patients achieved simultaneous 20/20 distance and J1 near vision and a pooled 91.2% accuracy within 0.50 diopters.
3. I Trust It with My Own Eyes Program
The company introduced the "I Trust It with My Own Eyes" initiative, highlighting ophthalmologists who have chosen the Light Adjustable Lens for themselves and sharing their personal experiences to build surgeon and patient confidence.
4. Expansion and Outlook
RxSight continues to expand its network of trained surgeons and certified practices across the U.S. and select international markets, reinforcing its strategy to establish adjustable intraocular lens technology as a standard of care in cataract surgery.